BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay $800M ...

The Company is also announcing that clinical test article manufacturing for all planned Study ... President of Lexaria Bioscience Corp. "Their nearly round-the-clock work has resulted in a rapid ...

Importantly, the Company continues to collect real-world data from the various challenging customer operations where these trucks are put to the test. From a fuel efficiency ... complete fuel cell ...